I-MAB Filed 2023 Annual Report on Form 20-F
Rhea-AI Summary
I-Mab, a global biotech company, filed its 2023 annual report on Form 20-F with the SEC. The report focuses on the development of immunotherapies for cancer treatment. It can be accessed on the company's investor relations website and the SEC's website. Shareholders and ADS holders can request hard copies free of charge.
Positive
- None.
Negative
- None.
News Market Reaction 1 Alert
On the day this news was published, IMAB declined 1.67%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
The annual report is available on the Company's investor relations website at ir.i-mabbiopharma.com and on the SEC's website at www.sec.gov. The Company will provide hard copies of the annual report, free of charge, to its shareholders and ADS holders upon written request. Requests should be directed to Investor Relations, I-Mab, 2440 Research Blvd., Suite 400,
About I-Mab
I-Mab (NASDAQ: IMAB) is a
I-Mab Contacts
Investors & Media |
Tyler Ehler |
Senior Director, Investor Relations |
View original content to download multimedia:https://www.prnewswire.com/news-releases/i-mab-filed-2023-annual-report-on-form-20-f-302130508.html
SOURCE I-Mab Biopharma